120 related articles for article (PubMed ID: 32366785)
1. The Use of Random Forests to Identify Brain Regions on Amyloid and FDG PET Associated With MoCA Score.
Zukotynski K; Gaudet V; Kuo PH; Adamo S; Goubran M; Scott CJM; Bocti C; Borrie M; Chertkow H; Frayne R; Hsiung R; Laforce R; Noseworthy MD; Prato FS; Sahlas DJ; Smith EE; Sossi V; Thiel A; Soucy JP; Tardif JC; Black SE
Clin Nucl Med; 2020 Jun; 45(6):427-433. PubMed ID: 32366785
[TBL] [Abstract][Full Text] [Related]
2. The Use of Random Forests to Classify Amyloid Brain PET.
Zukotynski K; Gaudet V; Kuo PH; Adamo S; Goubran M; Scott C; Bocti C; Borrie M; Chertkow H; Frayne R; Hsiung R; Laforce R; Noseworthy MD; Prato FS; Sahlas DJ; Smith EE; Sossi V; Thiel A; Soucy JP; Tardif JC; Black SE
Clin Nucl Med; 2019 Oct; 44(10):784-788. PubMed ID: 31348088
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease.
Bailly M; Ribeiro MJ; Vercouillie J; Hommet C; Gissot V; Camus V; Guilloteau D
Clin Nucl Med; 2015 Feb; 40(2):e111-6. PubMed ID: 25549345
[TBL] [Abstract][Full Text] [Related]
4. Correlation between brain glucose metabolism (
Albano D; Premi E; Peli A; Camoni L; Bertagna F; Turrone R; Borroni B; Calhoun VD; Rodella C; Magoni M; Padovani A; Giubbini R; Paghera B
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(3):146-152. PubMed ID: 35577490
[TBL] [Abstract][Full Text] [Related]
5. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images.
Joshi AD; Pontecorvo MJ; Lu M; Skovronsky DM; Mintun MA; Devous MD
J Nucl Med; 2015 Nov; 56(11):1736-41. PubMed ID: 26338898
[TBL] [Abstract][Full Text] [Related]
6. Predictive Value of
Blazhenets G; Ma Y; Sörensen A; Schiller F; Rücker G; Eidelberg D; Frings L; Meyer PT;
J Nucl Med; 2020 Apr; 61(4):597-603. PubMed ID: 31628215
[TBL] [Abstract][Full Text] [Related]
7. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
[TBL] [Abstract][Full Text] [Related]
8. Optimization of image reconstruction conditions with phantoms for brain FDG and amyloid PET imaging.
Akamatsu G; Ikari Y; Nishio T; Nishida H; Ohnishi A; Aita K; Sasaki M; Sasaki M; Senda M
Ann Nucl Med; 2016 Jan; 30(1):18-28. PubMed ID: 26337533
[TBL] [Abstract][Full Text] [Related]
9. Relationship Between the Japanese Version of the Montreal Cognitive Assessment and PET Imaging in Subjects with Mild Cognitive Impairment.
Eguchi A; Kimura N; Aso Y; Yabuuchi K; Ishibashi M; Hori D; Sasaki Y; Nakamichi A; Uesugi S; Jikumaru M; Sumi K; Shimomura T; Matsubara E
Curr Alzheimer Res; 2019; 16(9):852-860. PubMed ID: 31385770
[TBL] [Abstract][Full Text] [Related]
10. Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls.
Newberg AB; Arnold SE; Wintering N; Rovner BW; Alavi A
J Nucl Med; 2012 Jun; 53(6):902-7. PubMed ID: 22577238
[TBL] [Abstract][Full Text] [Related]
11. Optimal Target Region for Subject Classification on the Basis of Amyloid PET Images.
Carbonell F; Zijdenbos AP; Charil A; Grand'Maison M; Bedell BJ;
J Nucl Med; 2015 Sep; 56(9):1351-8. PubMed ID: 26135108
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.
Rodriguez-Vieitez E; Carter SF; Chiotis K; Saint-Aubert L; Leuzy A; Schöll M; Almkvist O; Wall A; Långström B; Nordberg A
J Nucl Med; 2016 Jul; 57(7):1071-7. PubMed ID: 26912447
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
[TBL] [Abstract][Full Text] [Related]
14. Amyloid burden in the hippocampus and default mode network: relationships with gray matter volume and cognitive performance in mild stage Alzheimer disease.
Chang YT; Huang CW; Chang YH; Chen NC; Lin KJ; Yan TC; Chang WN; Chen SF; Lui CC; Lin PH; Chang CC
Medicine (Baltimore); 2015 Apr; 94(16):e763. PubMed ID: 25906109
[TBL] [Abstract][Full Text] [Related]
15. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
16. Clinical, FDG and amyloid PET imaging in posterior cortical atrophy.
Singh TD; Josephs KA; Machulda MM; Drubach DA; Apostolova LG; Lowe VJ; Whitwell JL
J Neurol; 2015 Jun; 262(6):1483-92. PubMed ID: 25862483
[TBL] [Abstract][Full Text] [Related]
17. Impact of MRI-based Segmentation Artifacts on Amyloid- and FDG-PET Quantitation.
Högenauer M; Brendel M; Delker A; Därr S; Weiss M; Bartenstein P; Rominger A; Alzheimer's Disease Neuroimaging Initiative
Curr Alzheimer Res; 2016; 13(5):597-607. PubMed ID: 27025775
[TBL] [Abstract][Full Text] [Related]
18. Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia.
Akhtar RS; Xie SX; Chen YJ; Rick J; Gross RG; Nasrallah IM; Van Deerlin VM; Trojanowski JQ; Chen-Plotkin AS; Hurtig HI; Siderowf AD; Dubroff JG; Weintraub D
PLoS One; 2017; 12(5):e0177924. PubMed ID: 28542444
[TBL] [Abstract][Full Text] [Related]
19. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
[TBL] [Abstract][Full Text] [Related]
20. Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region.
Chen K; Roontiva A; Thiyyagura P; Lee W; Liu X; Ayutyanont N; Protas H; Luo JL; Bauer R; Reschke C; Bandy D; Koeppe RA; Fleisher AS; Caselli RJ; Landau S; Jagust WJ; Weiner MW; Reiman EM;
J Nucl Med; 2015 Apr; 56(4):560-6. PubMed ID: 25745091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
